Neurotech International Ltd. (AU:NTI) has released an update.
Neurotech International Ltd. has presented promising results from their Autism Phase II/III and Rett Syndrome Phase I/II clinical trials, alongside announcing a capital raise to further their mission of improving lives. The presentation aimed to provide general information about the company and was not an investment solicitation or advice. It also contained forward-looking statements, emphasizing that such predictions are subject to uncertainties and risks.
For further insights into AU:NTI stock, check out TipRanks’ Stock Analysis page.
